VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
FTH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
FTHFaeth Therapeutics, Inc.
$9.04$568M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
FTH logo

Faeth Therapeutics, Inc.

FTH
NASDAQ
$9.04
At close - Nov 17, 4:00 PM EST - USD
Market Cap$234M
P/E-1.1x
52W High$42.14
Volume754.15K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Clinical Burn Threatens Future Operational Viability

Sensei Biotherapeutics remains a pre-revenue entity heavily reliant on external capital to sustain its immuno-oncology pipeline, as evidenced by a cumulative deficit exceeding $283 million.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

FTH price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-104% Peers

P/E is 104% below peer median

03

Market leadership

RS 16 · Lag

Laggard (Underperforming 84% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 3

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
FTH-6.32%
S&P 500 (^GSPC)+7.21%
1-Year Return
FTH+11.06%
S&P 500 (^GSPC)+10.03%
3-Year Return
FTH-22.34%
S&P 500 (^GSPC)+58.72%
5-Year Return
FTH-95.14%
S&P 500 (^GSPC)+58.50%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$21M+30.1% YoY
Free cash flow FY25
-$20M+17.5% YoY
Operating margin FY25
-
ROIC (FY25)-76.6%
Avg ROIC 5Y-47.4%
ROE (TTM)-153.5%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (42%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 3, 2026
-$0.79-1.1%
vs -$0.78
—
vs —
Q3 2026
Aug 4, 2026
-$2.84-7.6%
vs -$2.64
—
vs —
Q2 2026
May 15, 2026
-$131.45-21101.6%
vs -$0.62
—
vs —
Q2 2026
Mar 30, 2026
-$3.74+22.2%
vs -$4.81
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Business Wire·Nov 11, 2026
Faeth Therapeutics to Participate in Upcoming November Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Wednesday, November 11, 2026 1x1 investor meetings Boston, MA Jefferies Global Healthcare Conference in London Tuesday, November 17, 2026 Presentation at 8:30.

Business Wire·Nov 9, 2026
Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced topline clinical data from its Phase 2 trial (FTH-PIK-201; NCT06463028; GOG-3111) of PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel to patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR (PAM) pathway mutation who ha.

Business Wire·Nov 6, 2026
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual event on Monday, November 9 at 8:00 AM ET to discuss topline results from its Phase 2 PIK-201 trial exploring PIKTOR in advanced endometrial cancer. To register, click here. The event will feature key opinion leader and PIK-201 principal investigator David Star.

Business Wire·Nov 5, 2026
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an aggregate of 68,000 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective November 4, 2026 pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment w.

Filtered for Faeth Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark FTH against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Faeth Therapeutics, Inc. (FTH)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
FTH logoFTHFaeth Therapeutics, Inc.Current
$9.04$233.6M-1.11——-153.55%—
IMVT logoIMVTImmunovant, Inc.
$33.21$6.85B-13.49—-7173.52%-63.01%—
ADCT logoADCTADC Therapeutics S.A.
$1.35$171.71M-2.5814.85%-96.66%——
IMCR logoIMCRImmunocore Holdings plc
$27.81$1.41B-58.9228.84%-6.05%-6.03%—
NKTX logoNKTXNkarta, Inc.
$1.25$89.43M-0.72——-48.58%—
CRVS logoCRVSCorvus Pharmaceuticals, Inc.
$10.17$855.2M-14.62——-34.98%—

Compare FTH vs Peers

Faeth Therapeutics, Inc. (FTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMVT

Most directly comparable listed peer for FTH.

Scale Benchmark

vs MRK

Larger-name benchmark to compare FTH against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMVT, ADCT, IMCR, NKTX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

FTH SEC Filings & Documents

Faeth Therapeutics, Inc. (FTH) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 3, 2026·SEC

Material company update

Oct 27, 2026·SEC

Material company update

Sep 17, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 30, 2026·SEC

FY 2025

Mar 28, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 3, 2026·SEC

FY 2026

Aug 4, 2026·SEC

FY 2026

May 15, 2026·SEC

Get notified when FTH posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

FTH Frequently Asked Questions

Faeth Therapeutics, Inc. (FTH) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
How fast is Faeth Therapeutics, Inc. growing?

Faeth Therapeutics, Inc. (FTH) grew revenue by 100.0% over the trailing twelve months, compared with the twelve months before.

Is FTH profitable?

No. Faeth Therapeutics, Inc. (FTH) reported a net loss of $211.4M over the trailing twelve months.

Dividend & Returns
What is FTH's return on equity?

Faeth Therapeutics, Inc. (FTH) had a return on equity (ROE) of -153.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Faeth Therapeutics, Inc.'s free cash flow?

Faeth Therapeutics, Inc. (FTH) had negative free cash flow of $43.3M over the trailing twelve months.

What if you invested $1,000 in FTH back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →